Added to YB: 2025-04-09
Pitch date: 2025-02-19
FULC [bullish]
Fulcrum Therapeutics, Inc.
+46.48%
current return
Author Info
No bio for this author
Company Info
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Market Cap
$207.8M
Pitch Price
$3.83
Price Target
8.80 (+57%)
Dividend
N/A
Sector
Pharmaceuticals
Category
value
Fulcrum Therapeutics, Inc. - $FULC
FULC: Biotech below cash post-lead asset failure. New focus: Pociredir for Sickle Cell Disease. Early data promising: dose-dependent HbF increase, improved markers. FDA restrictions may lift. $257M cash runway to 2027. Valuation: $8.80/sh (50% POS, 30% penetration). Risks: clinical failure, dilution. Catalysts: 12mg & 20mg data 2024, regulatory 2026.
Read full article (6 min)